Heron Therapeutics reported $140.64M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
ANI Pharmaceuticals USD 274.31M 5.84M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
Eisai JPY 184.62B 19M Sep/2026
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 544.86M 1.35M Sep/2026
Ligand Pharmaceuticals USD 1.13B 679.7M Jun/2026
Merck USD 49.69B 1.39B Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Omeros USD 403.72M 27.2M Jun/2024
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Veracyte USD 0 0 Mar/2025
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026